Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding lung cancer in the previous week. Topics include all stories related to lung cancer as well as personal stories and events.
Week ending November 2, 2014
November is Lung Cancer Awareness Month and The Caring Ambassadors Program is proud to announce the release of two new resources for people with lung cancer and their loved ones. The 2nd Edition of Lung Cancer Choices and a new publication, Caregiver Choices, were launched November 1 as part of Lung Cancer Awareness Month.
WASHINGTON Nov. 3 2014 /PRNewswire-USNewswire/ — “Lung Cancer Awareness Month this year is different and may be the most significant in history. By Nov. 10 Medicare must rule on coverage for computed tomography (CT) lung cancer screening – the first and only test proven to reduce lung cancer deaths. If Medicare will fully cover this exam for seniors at high risk for the disease we can complete the first major blow against the nation’s leading cancer killer.”
“The Northside Hospital Cancer Institute (NHCI) Lung Cancer Program features high levels of clinical expertise and comprehensive services rarely found in a community hospital setting.”
“Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, explains how resistance occurs when treating patients with lung cancer using EGFR TKI.”
“At his grandmother’s funeral more than a decade ago, Sal Yniguez resolved to stop smoking.”
“In many types of cancer, tumor cells undergo chromosomal rearrangements — complex genetic mutations in which stretches of DNA are reshuffled. Until now, this process has been difficult to reconstruct in lab mice, so scientists haven’t always been able to find out which chromosomal rearrangements are clinically important or how they enable tumors to thrive.”
KITCHENER — “The surgeon intently watches the video screen as the cancerous part of his patient’s lung is finally removed after a couple hours of painstaking work guided by a tiny camera slipped inside her chest.”
“Ingelheim, Germany, 7 November 2014 – Boehringer Ingelheim today announced data from a pre-specified subgroup-analysis of the pivotal Phase III LUX-Lung 3 trial which demonstrated that Asian non-small cell lung cancer (NSCLC) patients with the most common type of EGFR mutation, (exon 19 deletion; del19), lived significantly longer after receiving first-line treatment with afatinib compared to chemotherapy (33.3 vs 22.9 months, respectively).1 This equated to a significant 43% reduction in the risk of death.1 The data were presented today at the 2014 IASLC Asia Pacific Lung Cancer Conference (APLCC), in Kuala Lumpur.”
“Every 30 seconds somebody, somewhere, dies of lung cancer. This means that 1.59 million people die of the disease every year, with only 15% of patients alive five years after diagnosis. I find the current poor prognosis unacceptable, and as Chair of the Global Lung Cancer Coalition it is my ambition to improve outcomes for patients currently living with lung cancer, or who may develop the disease in the future.”
“My patient, “Judy,” is one of more than 224,000 Americans this year who will be diagnosed with lung cancer. And like most of her fellow lung cancer patients, she is struggling not only to learn all she can about her diagnosis and treatment options, but also to adjust to the overwhelming burden of shame and stigma that plagues this disease. When asked who is providing her with support, Judy said she is ashamed to admit her metastatic, incurable cancer diagnosis to loved ones, and that she is bearing the burden alone. Because one of the strongest risk factors for lung cancer is smoking, our society has come to the conclusion that people diagnosed with lung cancer somehow deserve it, that it was brought on by their own ‘bad’ behavior.”
“Removal of an entire lung lobe may offer patients with early stage lung cancer better overall survival compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a new study.”
“Spartanburg Regional Healthcare System has joined with the Lung Cancer Alliance, Vietnam Veterans of America, American Veterans and the Military Officers Association of America to offer free lung cancer screenings to former servicemen and women in time for Veterans Day.”